论文信息 - NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias. - 字舞流文

NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias.

P. Moayyedi | H. Barr | J. Jankowski | P. Watson | S. Attwood | R. Harrison | J. Decaestecker | J. deCaestecker

[1] Carissa A. Sanchez,et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.

[2] A. Bhattacharyya,et al. Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus , 2004, American Journal of Gastroenterology.

[3] Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus , 2004 .

[4] Janusz Jankowski,et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. , 2004, Gastroenterology.

[5] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[6] P. Moayyedi,et al. Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. , 2004, Journal of the National Cancer Institute.

[7] K. Kerlikowske,et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. , 2003, Gastroenterology.